Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Up 1,012.9% in December

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,090,000 shares, an increase of 1,012.9% from the December 15th total of 187,800 shares. Currently, 3.7% of the company’s stock are short sold. Based on an average daily volume of 6,360,000 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Trading Down 2.1 %

Shares of APTO stock traded down $0.00 on Monday, hitting $0.22. 464,872 shares of the stock were exchanged, compared to its average volume of 1,201,724. The firm’s 50 day moving average is $0.25 and its two-hundred day moving average is $0.40. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.42. The firm has a market capitalization of $12.96 million, a PE ratio of -0.07 and a beta of 0.87.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. StockNews.com initiated coverage on shares of Aptose Biosciences in a report on Wednesday, January 8th. They issued a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a research note on Friday.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.